Wyden, Senate Democrats Introduce Measure to Prevent Spike in Medicare Premiums
Medicare Part B Premiums and Deductibles Set for Dramatic Rise Next Year Without Congressional Action Bill Would Keep Premiums and Deductibles Affordable for Millions of Seniors WASHINGTON –Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and Senate Democrats today introduced legislation that would protect Medicare beneficiaries and states from a sharp rise in Part B […]
Wyden Statement on End of TPP Negotiations
WASHINGTON – Sen. Ron Wyden, D-Ore., ranking Democrat on the Senate Finance Committee, issued the following statement on the close of negotiations for the Trans-Pacific Partnership trade agreement between the United States and 11 other Pacific nations. “As I have said in the past, a good Trans-Pacific Partnership agreement could present important new opportunities for […]
Wyden Statement on Proposed Cuts to Multiemployer Pension Plan
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today a statement following news that Central States Pension Fund, which has 400,000 participants, has filed an application for the suspension of benefits (i.e. benefit cuts) with the Treasury Department under the Multiemployer Pension Reform Act of 2014. “These proposed benefit cuts are the result of bad […]
Wyden Statement at Finance Committee Hearing on Improper Payments
It’s important at the outset of this hearing to make sure that everyone is on the same page with respect to the topic at hand. In my view, there are two issues, which are related but distinct. The first is improper payments, which are payments that are too big, too small, or documented the wrong […]
Wyden Statement on Commencement of Atlanta TPP Ministerial
WASHINGTON– Sen. Ron Wyden, ranking Democrat on the Senate Finance Committee, issued the following statement on the start of the Trans-Pacific Partnership negotiating rounds in Atlanta: “This is a big week for trade negotiations,” Wyden said. “Key issues are still on the table and must be resolved. In my view it’s important that the U.S. […]
Wyden Statement at Finance Committee Hearing on Puerto Rico’s Economic Crisis
There are more than three million United States citizens living in the Commonwealth of Puerto Rico, where longstanding economic challenges have developed into a very real and very immediate crisis. No single policy or harsh austerity platform is going to save the day. The solutions in Puerto Rico must be focused, first and foremost, on […]
Wyden, Hatch, Markey Applaud Congressional Passage of Access to Clinical Trials Bill
WASHINGTON –Senate Finance Committee Ranking Member Ron Wyden, D-Ore., Senate Finance Committee Chairman Orrin Hatch, R-Utah, and Senator Edward J. Markey, D-Mass., today applauded the House of Representatives’ passage of the “Ensuring Access to Clinical Trials Act,” bipartisan legislation that makes it possible for people receiving Supplemental Security Income (SSI) and Medicaid to continue participating […]
Wyden Statement on the Social Security Disability Insurance Trust Fund
I want to take a few minutes today to discuss the enormous importance of America’s most critical safety net program — Social Security. In particular, I want to talk about the Social Security Disability Insurance program and introduce a proposal to secure the financing of Social Security. Of all the strands woven together in America’s […]
Congressional Democrats Introduce Bill to Secure Benefits for Americans with Disabilities
Bicameral Proposal Would Prevent Benefit Cuts at the End of 2016 and Ensure Earned Benefits Will Be Paid as Promised Bill Would Adjust Payroll Tax Revenue between Social Security Trust Funds—As Congress Has Done 11 Times Before on a Bipartisan Basis WASHINGTON –Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and House Ways & Means […]
Wyden Offers Support for Proposed Biosimilar Drug Payment Rule from CMS
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today sent a letter to the Centers for Medicare and Medicaid Services (CMS) offering support for their proposed rule on paying for biosimilar biological products (biosimilars): “Biosimilar products should compete with one another – rather than set their own price – to ensure patients have […]